Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus
MWN-AI** Summary
Mirum Pharmaceuticals, Inc. has announced significant advancements in its Phase 3 AZURE clinical program, which evaluates brelovitug for the treatment of chronic hepatitis delta virus (HDV). The company has completed enrollment for the AZURE-1 study and finished screening in the AZURE-4 study, both pivotal trials aiming to provide critical data for brelovitug’s U.S. Biologics License Application (BLA). Topline results from these studies are anticipated in the second half of 2026.
Brelovitug, a pan-genotypic human monoclonal antibody, has the FDA's Breakthrough Therapy designation, emphasizing its critical potential to address the unmet medical needs of patients suffering from HDV, a severe form of viral hepatitis without approved U.S. therapies. The condition is known for its rapid progression to liver fibrosis, cirrhosis, and an increased risk of liver cancer.
Dr. Joanne Quan, Chief Medical Officer at Mirum, noted that achieving these milestones enhances the company's trajectory toward seeking regulatory approval. Interim data from the AZURE-1 study is expected in the second quarter of 2026, with the primary endpoint focused on virologic response and normalization of ALT levels after 24 weeks of treatment, aligning with FDA guidelines for accelerated approval.
Both AZURE-1 and AZURE-4 involve treatment-naïve patients and are designed to evaluate different dosing regimens for brelovitug. The completion of these pivotal studies could set the stage for a potential launch in the U.S. in 2027. With strong antiviral activity demonstrated in earlier studies and an encouraging safety profile, the progress of brelovitug could provide a new, much-needed treatment option for patients battling chronic HDV.
MWN-AI** Analysis
Mirum Pharmaceuticals (NASDAQ: MIRM) is making notable strides in its clinical program for brelovitug, a treatment for chronic hepatitis delta virus (HDV). With enrollment completed in Phase 3 AZURE-1 and screening finalized for AZURE-4, investors have reason to watch closely as topline data is anticipated in the second half of 2026, pending a U.S. BLA submission shortly thereafter.
The aggressive nature of HDV, which has no approved therapies in the U.S., highlights the urgency and potential market impact of brelovitug. The drug has gained FDA Breakthrough Therapy designation, signaling regulatory support that can facilitate a faster approval pathway. This positions Mirum favorably within the competitive biopharmaceutical landscape, especially considering that the market for HDV treatments remains largely untapped.
Recent comments from executives underscore the significance of these studies. Positive interim results and final data confirming the efficacy and safety of brelovitug could substantially elevate the company’s profile and stock performance as pharmaceutical investments are often driven by clinical milestones. Moreover, brelovitug’s potential to achieve viral suppression and liver inflammation improvement addresses critical patient needs in a high-risk demographic.
Investors should keenly monitor the Phase 3 trial outcomes in 2026. Should brelovitug receive regulatory approval, it could transform Mirum’s financial outlook, as successful market entry can create a strong revenue stream from a currently underserved patient population. Given these developments, Mirum Pharmaceuticals presents a compelling opportunity for investors looking to engage with innovative therapies in the rare disease sector. However, they should be cautious of inherent risks in drug development and keep abreast of future announcements that could affect stock volatility.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Phase 3 AZURE-1 enrollment complete
- Phase 3 AZURE-4 screening complete
- Topline AZURE-1 and AZURE-4 results expected in 2H 2026
- AZURE-1 and AZURE-4 to form the basis of Mirum’s U.S. BLA Submission
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced completion of enrollment in the Phase 3 AZURE-1 study and completion of screening in the Phase 3 AZURE-4 study, both evaluating brelovitug for the treatment of chronic hepatitis delta virus (HDV). Achievement of these milestones confirms the expected timing of topline 24-week data in the second half of 2026. AZURE-1 and AZURE-4 together will form the basis of Mirum’s U.S. BLA submission for brelovitug, which has received Breakthrough Therapy designation from the FDA for the treatment of chronic HDV infection.
Brelovitug is being developed for HDV, the most severe form of viral hepatitis, and a disease with no approved therapies in the U.S. HDV occurs in people already infected with hepatitis B virus (HBV) and is associated with rapid progression to liver fibrosis, cirrhosis, liver cancer, and liver-related death.
“The completion of AZURE-1 enrollment and AZURE-4 screening represent important execution milestones as we advance brelovitug through the Phase 3 AZURE program,” said Joanne Quan, M.D., Chief Medical Officer at Mirum Pharmaceuticals. “We look forward to reporting interim data from AZURE-1 in the second quarter and topline results from AZURE-1 and AZURE-4 in the second half of 2026. Both studies are evaluating a composite endpoint of virologic response and ALT normalization at 24 weeks, aligned with FDA guidance for accelerated approval in HDV, and building on the strong antiviral activity observed in our Phase 2 study.”
“HDV is an aggressive disease that progresses quickly and leaves patients with very limited treatment options,” said Tatyana Kushner, M.D., MSCE, Associate Professor of Medicine, Division of Gastroenterology and Hepatology at Weill Cornell Medicine. “Having a well-tolerated single-agent therapy that achieves viral suppression and improves liver inflammation is critical for patients with HDV, and the progress of these Phase 3 studies brings us closer to potentially delivering a new therapy to patients in urgent need.”
Topline data from AZURE-1 and AZURE-4 are expected in 2H 2026, with a potential BLA submission and launch in the U.S. in 2027.
About Brelovitug
Brelovitug is an investigational, highly potent, pan-genotypic, fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets the surface antigen (anti-HBsAg) on both the chronic hepatitis delta virus (HDV) and the hepatitis B virus (HBV). Brelovitug is designed to neutralize and remove hepatitis B and hepatitis D virions and deplete HBsAg-containing subviral particles. Brelovitug has FDA Breakthrough Therapy designation for the treatment of chronic HDV infection and PRIME and Orphan designations from the European Medicines Agency. In the Phase 2 study, brelovitug demonstrated strong antiviral activity in HDV, achieving a 100% HDV RNA response, along with improvements in liver enzyme levels and a favorable safety profile, with the most common adverse event being injection-site erythema. Mirum owns worldwide rights to brelovitug.
About the AZURE Clinical Program
The AZURE program is a global, registrational Phase 3 clinical development program evaluating brelovitug for the treatment of chronic hepatitis delta virus (HDV). The program includes multiple open-label studies designed to assess the primary endpoint of combined virologic and biochemical response. Together, the studies are intended to support regulatory filings in the United States and Europe.
About AZURE-1 and AZURE-4
AZURE-1 and AZURE-4 are Phase 3 studies that form the basis of Mirum’s U.S. FDA BLA submission for brelovitug in chronic hepatitis delta virus (HDV).
AZURE-1 is evaluating approximately 200 treatment-naïve patients randomized in a 2:2:1 ratio to receive brelovitug 300 mg once weekly, brelovitug 900 mg once monthly, or 24-week delayed therapeutic start. AZURE-4 is evaluating approximately 80 treatment-naïve patients randomized in a 2:1:1 ratio to receive brelovitug 300 mg once weekly, brelovitug 900 mg once monthly, or 12-week delayed therapeutic start. Patients randomized to delayed treatment initiate brelovitug 300 mg once weekly upon completion of the treatment delay in both studies. AZURE-4 is being conducted in partnership with PSI CRO.
The primary endpoint for both studies is the proportion of patients achieving combined virologic response and ALT normalization at Week 24, consistent with FDA guidance for accelerated approval in HDV. Both studies include open-label extension periods of up to 96 weeks.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum combines deep rare disease expertise with strong connections to patient communities.
The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX). Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV) and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS).
Mirum’s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at www.mirumpharma.com and follow Mirum on Facebook , LinkedIn , Instagram and X .
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, expected timing of topline data for the AZURE studies or BLA submission, the quality of data to be submitted for a brelovitug BLA application in the US, the relationship of antiviral activity as an important endpoint in HDV and the success or approval of any potential regulatory submission for brelovitug. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipate,” “expected,” “will,” “could,” “would,” “potential,” “continue,” “plans,” “intended,” “believe,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Mirum’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the development of acquired product candidates, including the failure of any expected synergies to be realized; risk and uncertainties arising from the integration of an acquired company, its employees and its assets with Mirum’s business; risks associated with evaluating companies and assets for acquisition, including that the perceived benefits of the acquisition are not realized; risks and uncertainties with the development of investigational medicines generally, including the failure of future studies to generate the same or similar data as prior studies and the potential that estimated prevalences are materially inaccurate; the risks and uncertainties associated with Mirum’s business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Mirum’s Annual Report for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 26, 2025, and subsequent filings with the Securities and Exchange Commission, which are available at www.sec.gov . All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260305481077/en/
Investor Contact:
Andrew McKibben
ir@mirumpharma.com
Media Contact:
Meredith Kiernan
Media@mirumpharma.com
FAQ**
How will the completion of Phase 3 AZURE-1 and AZURE-4 studies impact investor confidence in Mirum Pharmaceuticals Inc. (MIRM) as they work towards a potential U.S. BLA submission in 2027?
What lessons can be learned from previous Phase 2 results that might inform the topline AZURE-1 and AZURE-4 outcomes for Mirum Pharmaceuticals Inc. (MIRM)?
Given the breakthrough therapy designation from the FDA, what are the expected market implications for Mirum Pharmaceuticals Inc. (MIRM) should brelovitug demonstrate positive results in the upcoming studies?
In what ways does the successful execution of the AZURE program position Mirum Pharmaceuticals Inc. (MIRM) competitively within the rare disease treatment market, particularly for chronic hepatitis delta virus (HDV)?
**MWN-AI FAQ is based on asking OpenAI questions about Mirum Pharmaceuticals Inc. (NASDAQ: MIRM).
NASDAQ: MIRM
MIRM Trading
-4.12% G/L:
$86.77 Last:
225,254 Volume:
$86.01 Open:
